For over a decade Sandoz, a Novartis division, has been the pioneer and global leader in biosimilars. This year marks ten years since Sandoz launched the world’s first biosimilar, Omnitrope®, in the EU, giving rise to the era of affordable biologics that have helped to treat millions of patients and liberate billions of dollars in healthcare costs. We continue to invest in research and development into these life changing medicines.
Sandoz calls for united action to improve patient access to biologics at Medicines for Europe Conference
April 28, 2016
Today Carol Lynch, Global Head of Biopharmaceuticals, Sandoz, will deliver a presentation titled The Biosimilar Market Leader’s Perspective at the 14th EBG conference in London....
Sandoz has world-class expertise in the development, manufacture and delivery of biosimilar medicines to help patients and the healthcare community.Read more
Sandoz is dedicated to improving patients’ lives and liberating healthcare resources, by increasing access to high-quality, affordable biosimilars.Read more